Boston, MA – [Insert Date] – Aclaris Therapeutics announced today that its investigational monoclonal antibody, bosakitug, did not demonstrate significant clinical benefit in a Phase II trial for patients with atopic dermatitis (AD). The ADMIRATION trial (NCT07011706) failed to achieve its primary or secondary efficacy endpoints, marking a setback for the company’s AD pipeline and prompting a strategic pivot towards its oral kinase inhibitor programs.
Despite the disappointing clinical outcomes, the company reported that bosakitug exhibited "robust target engagement" of thymic stromal lymphopoietin (TSLP) and a downregulation of biomarkers associated with immune activation, including Th1, Th2, and Th17 pathways. These pharmacodynamic (PD) results suggest the drug’s biological mechanism of action was indeed engaged, though this did not translate into observable clinical improvement for AD patients in this study. Bosakitug was generally well-tolerated by participants throughout the trial.
This outcome underscores the persistent challenges in developing effective treatments for atopic dermatitis, a chronic and often debilitating inflammatory skin condition. The failure of bosakitug, an anti-TSLP monoclonal antibody, highlights the complexities of targeting single pathways in a multifaceted disease.
Dismal Trial Results and Strategic Reorientation
The ADMIRATION trial was designed to evaluate the safety and efficacy of bosakitug in adult patients with moderate to severe atopic dermatitis. The trial’s primary endpoint likely focused on a significant reduction in disease severity, as measured by established clinical scales such as the Eczema Area and Severity Index (EASI) or the Investigator’s Global Assessment (IGA) score. The failure to meet these primary objectives, along with secondary endpoints that typically assess measures like itch reduction or quality of life improvements, represents a significant blow to the drug’s development prospects in this indication.
In the wake of these results, Aclaris Therapeutics is reaffirming its commitment to other promising areas of its pipeline. Dr. Neal Walker, CEO of Aclaris, expressed his disappointment but quickly pivoted to highlight the company’s continued focus on its oral kinase inhibitors and its bispecific antibody, ATI-052, which targets both TSLP and IL-4Rα.
"We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone," stated Dr. Walker. "We are grateful to the patients and investigators whose participation and commitment made this study possible. These results do not change our development priorities, which remain focused on our oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052."
This strategic shift means that Aclaris will be intensifying its efforts on developing oral therapies, which often offer greater convenience and potentially different efficacy profiles compared to injectable biologics. The company’s pipeline includes modzatinib, an oral ITK/JAK3 inhibitor, for which a Phase IIb trial in lichen planus is slated to commence. Additionally, ATI-052, a bispecific antibody targeting both TSLP and IL-4Rα, is scheduled for a Phase IIb trial in eosinophilic esophagitis in the first quarter of 2027. The company has also successfully completed Investigational New Drug (IND)-enabling studies for ATI-9494, another oral ITK inhibitor, paving the way for future clinical development.
A Glimpse into the Bosakitug Development Journey
Aclaris Therapeutics had secured the rights for the development, manufacturing, and commercialization of bosakitug from Biosion in November 2024. This licensing agreement granted Aclaris exclusive rights to the drug in all global regions outside of Greater China. The acquisition of these rights indicated Aclaris’s strategic interest in the potential of TSLP inhibition for inflammatory diseases, particularly atopic dermatitis.
Thymic stromal lymphopoietin (TSLP) is a cytokine that plays a crucial role in initiating and perpetuating type 2 inflammatory responses, which are central to the pathogenesis of atopic dermatitis. By blocking TSLP, bosakitug was intended to interrupt this inflammatory cascade, thereby reducing skin inflammation, itching, and other symptoms associated with AD. The Phase II trial was designed to validate whether this mechanism, when translated into a humanized monoclonal antibody, could achieve meaningful clinical improvements for patients suffering from this chronic condition.

The ADMIRATION trial’s design likely incorporated a placebo-controlled, randomized approach to ensure the robustness of its findings. The inclusion of both primary and secondary endpoints is standard practice in clinical trials to provide a comprehensive assessment of a drug’s efficacy and safety. While the pharmacodynamic data indicating "robust target engagement" and biomarker modulation are scientifically interesting, they highlight a potential disconnect between biological activity and clinical benefit, a challenge that has been observed with other therapeutic candidates in various disease areas.
The Competitive Landscape of Atopic Dermatitis
The atopic dermatitis market is highly competitive, characterized by the presence of established blockbuster therapies and a robust pipeline of novel agents. Sanofi’s Dupixent (dupilumab), a monoclonal antibody targeting the IL-4 receptor alpha subunit, has been a dominant force in the AD market for years. Similarly, AbbVie’s Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, has also gained significant traction.
The impending patent expiry of some of these key therapies is spurring innovation and strategic planning among pharmaceutical companies. Sanofi, for instance, is already advancing its next-generation therapy, amlitelimab, which has demonstrated success in a Phase III trial and is currently seeking regulatory approval. This proactive approach underscores the dynamic nature of the AD market and the constant drive for improved treatment options.
Beyond these established players, other companies are also vying for a share of the growing AD market. Nektar Therapeutics is exploring rezpeg (rezpegaldesleukin) for AD, with Phase II data suggesting potential benefits across different dosing regimens, including a notable quarterly maintenance dosing strategy that has garnered attention from key opinion leaders.
Market Projections and Future Outlook
The significant unmet need in atopic dermatitis, coupled with an aging global population and increasing awareness of the disease, is driving substantial market growth. According to a GlobalData report, the atopic dermatitis market was valued at $8.5 billion in 2023 across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). This figure is projected to escalate to $21.5 billion by 2033, reflecting a compound annual growth rate (CAGR) of 9.8%. This impressive growth trajectory underscores the immense commercial potential for effective and innovative treatments in this therapeutic area.
The failure of bosakitug in the ADMIRATION trial, while a setback for Aclaris Therapeutics, does not diminish the overall opportunity within the AD market. Instead, it highlights the intricate biological pathways involved and the challenges of translating preclinical and early-phase mechanistic insights into clinically meaningful outcomes for patients.
Aclaris’s strategic redirection towards its oral kinase inhibitors and bispecific antibody candidates suggests a belief that these modalities may hold greater promise for addressing the complex needs of AD patients or other inflammatory conditions. The company’s continued investment in these programs, alongside its ongoing research into other indications like lichen planus and eosinophilic esophagitis, indicates a resilient approach to drug development.
The pharmaceutical industry’s pursuit of better AD treatments remains intense. The insights gained from trials like ADMIRATION, even in failure, contribute valuable knowledge to the scientific community, informing future research and the development of more targeted and effective therapies. As the market continues to expand, the focus will remain on identifying candidates that can offer significant clinical differentiation, improved patient convenience, and a favorable safety profile in the fight against atopic dermatitis.
